HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

RB Starts ‘Supercharge’ Diet To Be ‘Leaner, More Agile’ In Consumer Health

This article was originally published in The Tan Sheet

Executive Summary

RB expects its “supercharge” cost-cutting strategy to yield as much as $228.5 million in annualized cost savings. The Mucinex marketer also says by 2020 it should compete almost exclusively in the consumer health, personal and household care markets.

You may also be interested in...



Consumer Health Care Products Industry Earnings Roundup

Pfizer Likes Consumer, But Not U.S. Tax Policy; Consumer Segment Stays At Reckitt, Rx To Leave; Merck Consumer Brands Strong With Division Sale Pending; Exchange Rates Deflate Bayer Growth; No Buyer’s Remorse At Sanofi; and Gummy Vitamin Business Soars For C&D

Flonase Switch Approved, Branded Nasal Allergy Spray Market Will Grow In 2015

Glaxo says Flonase Allergy Relief (fluticasone propionate 50 mcg spray) is the “first OTC nasal spray indicated for relief of all nasal and eye-related allergy symptoms.” The firm has not learned from FDA whether Flonase Allergy Relief will launch with market exclusivity.

‘Supplement’ On CBD Product Label A Bullseye For US Litigants, Says Attorney

Two CBD marketers warned by FDA in a recent crackdown are targeted in class action complaints alleging they made unsubstantiated health claims and mislabeled ‘illegal drug’ products as supplements. Complaints are a wake-up call to CBD wellness industry to ensure claims are substantiated, as the class action bar is on the prowl following the agency’s 15 warning letter blast in November.

Topics

Related Companies

UsernamePublicRestriction

Register

RS123366

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel